Recap: Teva Pharmaceutical Q2 Earnings

Shares of Teva Pharmaceutical Industries TEVA rose 5% in pre-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share fell 8.33% year over year to $0.55, which beat the estimate of $0.53.

Revenue of $3,870,000,000 declined by 10.77% from the same period last year, which missed the estimate of $3,930,000,000.

Outlook

The upcoming fiscal year's EPS expected to be between $2.30 and $2.55.

The upcoming fiscal year's revenue expected to be between $16,600,000,000 and $17,000,000,000.

Details Of The Call

Date: Aug 05, 2020

Time: 08:00 AM

ET Webcast URL: https://digital.vevent.com/index.jsp?eid=7985&seid=6001

Price Action

Company's 52-week high was at $13.76

Company's 52-week low was at $6.07

Price action over last quarter: Up 4.52%

Company Profile

Headquartered in Israel, Teva Pharmaceutical is the largest generic drug manufacturer in the world with roughly 60 manufacturing and R&D facilities. The company was formed in 1901 and has a portfolio of more than 3,500 medicines--roughly 1 out of 9 generic prescriptions in the U.S. is filled with a Teva product. The company also develops branded pharmaceuticals in the central nervous system, oncology, and respiratory categories. Teva's generic drug sales represent slightly over half of total revenue, with branded drug and distribution revenue making up the balance. Teva is an aggressive filer to bring generic drugs to market when brand patents expire and has the most generic products pending Food and Drug Administration approval.